

REMARKS

Following entry of the foregoing amendments, claims 1 to 13, 15, 16, and 24 will be pending in the application. Claim 24 has been amended, and claims 23 and 25 to 29 have been canceled, herein, without prejudice. No new claims have been added. Support for the amendments is found throughout the specification as originally filed. No new matter has been added.

Applicants respectfully request reconsideration of the rejections of record in view of the foregoing amendments and the following remarks.

Withdrawn Subject Matter

The Office action identifies certain "elected subject matter" and indicates that the remaining subject matter in claims 1 to 13, 15, and 16 has been withdrawn from consideration as drawn to "non-elected inventions."¹ A restriction requirement was not issued by the Patent Office in connection with the application, however, nor was an election of species requirement, and Applicants accordingly have not elected particular subject matter for prosecution on the merits. Applicants' undersigned representative spoke to the Examiner on February 1, 2006 by telephone regarding the withdrawn subject matter, and the Examiner indicated that the subject matter would be reinstated upon a written request to do so in response to the Office action. Applicants accordingly traverse the withdrawal of particular subject matter from claims 1 to 13, 15, and 16, and respectfully ask the Examiner to reinstate the withdrawn subject matter and search and examine the full scope of the subject matter encompassed by the pending claims.

¹ Office Action dated January 18, 2006, pages 3 to 4.

DOCKET NO.: CELL-0286
Application No.: 10/506,388
Office Action Dated: January 18, 2006

PATENT

Alleged Lack of Enablement


Claims 23, 24, 25 (in part), and 26 to 29 have been rejected under 35 U.S.C. § 112, first paragraph for lack of enablement because the specification allegedly does not enable methods for inhibiting heparanase activity in patients and methods for treating most cancers, angiogenesis-related disorders, inflammatory diseases, autoimmune disorders, cardiovascular diseases, and renal disorders. The Office action indicates, however, that the specification enables methods for treating melanoma. Without conceding the correctness of the assertions, claims 23 and 25 to 29 have been canceled, and claim 24 has been amended to recite methods for treating melanoma. As indicated in the Office action, the methods for treating melanoma recited in claim 24 are fully enabled by the specification, and Applicants accordingly, respectfully request withdrawal of the rejection.

Conclusion

Applicants believe that the foregoing constitutes a complete and full response to the Office action of record. Accordingly, an early and favorable action is respectfully requested.

Respectfully submitted.

Date: April 17, 2006



Jane E. Ingles, Ph.D.
Registration No. 48,444

Woodcock Washburn LLP
One Liberty Place - 46th Floor
Philadelphia PA 19103
Telephone: (215) 568-3100
Facsimile: (215) 568-3439